BP
PDLI

Banyan Partners’s PDL BioPharma, Inc. PDLI Stock Holding History

Banyan Partners’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-21,613
Closed -$172K – 465
2013
Q3 		$172K Buy
+21,613
New +$174K 0.02% 329

Other funds holding PDLI

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

Banyan Partners's PDLI Position: Q4 2013 in Review

Banyan Partners sold out of PDL BioPharma, Inc. (PDLI) in Q4 2013, closing a stake of 21,613 shares — an estimated $172K sold.

Banyan Partners first reported a position in PDLI in Q3 2013 and held it in 1 quarter. The position peaked at $172K in Q3 2013. 224 funds tracked by Wall St. Rank hold PDLI as of Q4 2013.

  • Banyan Partners reported no remaining PDL BioPharma, Inc. position as of Q4 2013 after selling out during the quarter.
  • Banyan Partners sold 21,613 PDL BioPharma, Inc. shares in Q4 2013, an estimated $172K.
  • Banyan Partners first reported a position in PDL BioPharma, Inc. in Q3 2013 and held it in 1 quarter.
  • Banyan Partners's PDL BioPharma, Inc. position peaked at $172K in Q3 2013.
  • 224 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2013.

Based on Banyan Partners's 13F filing for Q4 2013, filed 12 Feb 2014.